News and

A New Publication Highlights the Use of cResponse in the Assessment of Response to Treatments for Pancreatic Cancer

A recent study led by Dr. Talia Golan from the Sheba Medical Center and Dr. Chani Stossel at the Oncology Institute titled; Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting studied 125 patients with this kind of cancer, grouping them by how they responded to certain cancer drugs.

A test called cResponse, developed by Curesponse and the Weizmann Institute of Science, was used to predict how well tumors would respond to drugs. The test can detect how the drugs and drug combinations worked in patients and in the tumor models.

The research found that while glBRCA pancreatic cancer can be treated with these drugs, often the cancer becomes resistant. The models they created help in understanding this resistance and could be used to find new drugs.

Dr. Vered Bar from Curesponse said that the study showed their cResponse test could help doctors choose better treatments for cancer patients. The cResponse system uses fast genetic sequencing and a special assay to see how cancer tissue reacts to drugs while keeping the tumor’s natural environment. It’s the first test of its kind that can show how a patient’s tumor reacts to different drugs in about two weeks after getting a tissue sample. This can be used for many types of cancer treatments.

The cResponse test is officially approved in Europe and follows international laboratory standards. In Israel, some insurance plans cover it. They plan to offer it to cancer patients in the UK, EU, and the USA starting in 2024.

To read the full article click here.

Want to know more?

Contact Us